Literature DB >> 16474401

Disruption of PTEN coupling with 5-HT2C receptors suppresses behavioral responses induced by drugs of abuse.

Shao-Ping Ji1, Yun Zhang, Jamie Van Cleemput, Wen Jiang, Mingxia Liao, Lei Li, Qi Wan, Jon R Backstrom, Xia Zhang.   

Abstract

The widespread distribution of the tumor suppressor PTEN (phosphatase and tensin homolog deleted on chromosome 10) in the adult brain suggests its role in a broad range of brain functions. Here we show evidence supporting a physical interaction of PTEN with a region in the third intracellular loop (3L4F) of the serotonin 5-HT2C receptor (5-HT2cR, formerly 5-HT1c receptor) in cell cultures. PTEN limits agonist-induced phosphorylation of 5-HT2cR through its protein phosphatase activity. We showed the probable existence of PTEN:5-HT2cR complexes in putative dopaminergic neurons in the rat ventral tegmental area (VTA), a brain region in which virtually all abused drugs exert rewarding effects by activating its dopamine neurons. We synthesized the interfering peptide Tat-3L4F, which is able to disrupt PTEN coupling with 5-HT2cR. Systemic application of Tat-3L4F or the 5-HT2cR agonist Ro600175 suppressed the increased firing rate of VTA dopaminergic neurons induced by delta9-tetrahydrocannabinol (THC), the psychoactive ingredient of marijuana. Using behavioral tests, we found that Tat-3L4F or Ro600175 blocks conditioned place preference of THC or nicotine, and that Ro600175, but not Tat-3L4F, produces anxiogenic effects, penile erection, hypophagia and motor functional suppression. These results suggest a potential strategy for treating drug addiction with the Tat-3L4F peptide.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16474401     DOI: 10.1038/nm1349

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  46 in total

Review 1.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 2.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

Review 3.  Serotonin2C receptors and drug addiction: focus on cocaine.

Authors:  Céline Devroye; Malgorzata Filip; Edmund Przegaliński; Andrew C McCreary; Umberto Spampinato
Journal:  Exp Brain Res       Date:  2013-06-08       Impact factor: 1.972

Review 4.  Signalling bias in new drug discovery: detection, quantification and therapeutic impact.

Authors:  Terry Kenakin; Arthur Christopoulos
Journal:  Nat Rev Drug Discov       Date:  2012-02-15       Impact factor: 84.694

5.  Targeting the cis-dimerization of LINGO-1 with low MW compounds affects its downstream signalling.

Authors:  L Cobret; M L De Tauzia; J Ferent; E Traiffort; I Hénaoui; F Godin; E Kellenberger; D Rognan; J Pantel; H Bénédetti; S Morisset-Lopez
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

6.  Pharmacological Modulation of 5-HT2C Receptor Activity Produces Bidirectional Changes in Locomotor Activity, Responding for a Conditioned Reinforcer, and Mesolimbic DA Release in C57BL/6 Mice.

Authors:  Caleb J Browne; Xiaodong Ji; Guy A Higgins; Paul J Fletcher; Colin Harvey-Lewis
Journal:  Neuropsychopharmacology       Date:  2017-06-13       Impact factor: 7.853

Review 7.  Plasticity of addiction: a mesolimbic dopamine short-circuit?

Authors:  Jason L Niehaus; Nelson D Cruz-Bermudez; Julie A Kauer
Journal:  Am J Addict       Date:  2009 Jul-Aug

8.  Selective deletion of PTEN in dopamine neurons leads to trophic effects and adaptation of striatal medium spiny projecting neurons.

Authors:  Oscar Diaz-Ruiz; Agustin Zapata; Lufei Shan; YaJun Zhang; Andreas C Tomac; Nasir Malik; Fidel de la Cruz; Cristina M Bäckman
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

9.  NO signaling and S-nitrosylation regulate PTEN inhibition in neurodegeneration.

Authors:  Young-Don Kwak; Tao Ma; Shiyong Diao; Xue Zhang; Yaomin Chen; Janet Hsu; Stuart A Lipton; Eliezer Masliah; Huaxi Xu; Francesca-Fang Liao
Journal:  Mol Neurodegener       Date:  2010-11-10       Impact factor: 14.195

10.  Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN.

Authors:  L Davidson; H Maccario; N M Perera; X Yang; L Spinelli; P Tibarewal; B Glancy; A Gray; C J Weijer; C P Downes; N R Leslie
Journal:  Oncogene       Date:  2009-11-16       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.